Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

BACKGROUND: In clinical practice the gold standard method to assess BRAF status in patients with metastatic melanoma is based on molecular assays. Recently, a mutation-specific monoclonal antibody (VE1), which detects the BRAF V600E mutated protein, has been developed. With this study we aimed to co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Schirosi, Laura, Strippoli, Sabino, Gaudio, Francesca, Graziano, Giusi, Popescu, Ondina, Guida, Michele, Simone, Giovanni, Mangia, Anita
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5116153/
https://ncbi.nlm.nih.gov/pubmed/27863476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2951-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares